| Trial name or title | Impact of icosapent ethyl on Alzheimer's disease (AD) biomarkers in preclinical adults |
| Methods | RCT |
| Participants | Cognitively healthy adults aged 50 to 70 years whose parents had AD |
| Interventions | Each for 18 months: Arm 1: Icosapent ethyl EPA (Vascepa) 4 g/d gel cap Arm 2: matching gel cap placebo |
| Outcomes | Primary: cerebral blood flow by MRI (magnetic resonance imaging) Secondary: CSF biomarkers of AD, cognitive performance (preclinical Alzheimer's cognitive composite, PACC) |
| Starting date | Registered on trials registry: 21 March 2016 Study start date: December 2016 Estimated study completion date: November 2021 |
| Contact information | Cynthia Carlsson, cynthia.carlsson@va.gov; Elena Beckman, elena.beckman@va.gov |
| Notes | NCT02719327 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.